Associate Professor Borislava Mihaylova
- Health Economics Research Centre
Borislava (Boby) Mihaylova is an Associate Professor and Senior Health Economist at the Health Economics Research Centre at the University of Oxford. Her research programme focuses on economic aspects of chronic disease (such as cardiovascular, chronic kidney disease and diabetes) and comprises studies of the impact of disease events and interventions on morbidity, mortality, health-related quality of life and healthcare costs; development of disease models to evaluate long-term effects of disease and interventions, cost-effectiveness analyses of healthcare interventions and studies of socio-economic determinants of health. She is leading the development of the economic analyses in a number of large randomised controlled trials (SHARP, THRIVE, REVEAL and ACST-2) and in the individual participant data meta-analysis of statin trials (Cholesterol Treatment Collaboration). Her work on effectiveness and cost-effectiveness of statins for cardiovascular disease prevention in the Heart Protection Study and the Cholesterol Treatment Collaboration has been influential in informing treatment recommendations for people at different vascular disease risk.
Socioeconomic differences in health-care use and outcomes for stroke and ischaemic heart disease in China during 2009-16: a prospective cohort study of 0·5 million adults.
Levy M. et al, (2020), Lancet Glob Health, 8, e591 - e602
Body Mass Index and cause-specific hospital admissions and costs: the UK Biobank Cohort Study
O’Halloran R. et al, (2020), Obesity
2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk (vol 290, pg 140, 2019)
Mach F. et al, (2020), ATHEROSCLEROSIS, 292, 160 - 162
Essential items for a Health Economics Analysis Plan (HEAP): expert Delphi consensus survey
Thorn J. et al, (2019), TRIALS, 20
Declining socioeconomic inequalities in hospital care use and case fatality rates for stroke and ischaemic heart disease in China during 2009-16: a prospective study of 0.5 million adults
Levy M. et al, (2019), LANCET, 394, 9 - 9